title: The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma.
abstract: Human prostate cancer is known to harbor recurrent genomic aberrations consisting of chromosomal losses, gains, rearrangements, and mutations that involve oncogenes and tumor suppressors. Genetically engineered mouse (GEM) models have been constructed to assess the causal role of these putative oncogenic events and provide molecular insight into disease pathogenesis. While GEM models generally initiate neoplasia by manipulating a single gene, expression profiles of GEM tumors typically comprise hundreds of transcript alterations. It is unclear whether these transcriptional changes represent the pleiotropic effects of single oncogenes, and/or cooperating genomic or epigenomic events. Therefore, it was determined whether structural chromosomal alterations occur in GEM models of prostate cancer and whether the changes are concordant with human carcinomas. Whole genome array-based comparative genomic hybridization (CGH) was used to identify somatic chromosomal copy number aberrations (SCNA) in the widely used TRAMP, Hi-Myc, Pten-null, and LADY GEM models. Interestingly, very few SCNAs were identified and the genomic architecture of Hi-Myc, Pten-null, and LADY tumors were essentially identical to the germline. TRAMP neuroendocrine carcinomas contained SCNAs, which comprised three recurrent aberrations including a single copy loss of chromosome 19 (encoding Pten). In contrast, cell lines derived from the TRAMP, Hi-Myc, and Pten-null tumors were notable for numerous SCNAs that included copy gains of chromosome 15 (encoding Myc) and losses of chromosome 11 (encoding p53).
  
  
  CONCLUSIONS
  Chromosomal alterations are not a prerequisite for tumor formation in GEM prostate cancer models and cooperating events do not naturally occur by mechanisms that recapitulate changes in genomic integrity as observed in human prostate cancer.
authors.affiliation: Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors.forename: Daniella
authors.initials: D
authors.lastname: Bianchi-Frias
authors.affiliation: Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors.forename: Susana A
authors.initials: SA
authors.lastname: Hernandez
authors.affiliation: Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors.forename: Roger
authors.initials: R
authors.lastname: Coleman
authors.affiliation: Department Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California.
authors.forename: Hong
authors.initials: H
authors.lastname: Wu
authors.affiliation: Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. pnelson@fhcrc.org.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Nelson
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology*; D000818:Animals; D045744:Cell Line, Tumor; D002869:Chromosome Aberrations; D033481:Chromosomes, Mammalian / Q000235:genetics*; D055028:Comparative Genomic Hybridization; D056915:DNA Copy Number Variations; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009374:Neoplasms, Experimental; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*